ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1685

Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014

Patompong Ungprasert1, Matthew Koster 2, Wisit Cheungpasitporn 3, Karn Wijarnpreecha 4, Charat Thongprayoon 2 and Paul Kroner 5, 1Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, 2Mayo Clinic Rochester, Rochester, MN, 3University of Mississippi Medical Center, Jackson, MS, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic Florida, Jacksonville

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: comorbidity and administrative databases, cost, Epidemiologic methods, Polyarteritis nodosa

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with PAN.  The current study was conducted with the aim to better describe those information using data from a large national database.

Methods: Patients with PAN were identified from the Nationwide Inpatient Sample (NIS) database for the year 2014 using ICD-9 diagnostic codes.  The primary outcome was determining the inpatient prevalence of PAN in hospitalized patients in the US.  Secondary outcomes included determining inpatient mortality, morbidity, comorbidities, hospital length of stay (LOS) and expenditures.  Expenditures were sub-divided into total hospitalization charges and hospital costs.  Total hospital charges represent the amount of money that each hospital billed the payers for the service provided during each admission, while hospital costs represent the amount of money the hospital invested to provide care during each admission.  A cohort of patients without PAN was also identified from the same database to serve as comparators for analysis of comorbidities.  Multivariate regression analysis was used to adjust for age, sex, ethnicity and hospital characteristics.

Results: A total of 4,110 patients with PAN were included in the study.  The mean age was 59.5 years and 61% were female.  The inpatient prevalence of PAN was 11.6 cases per 100,000 admissions.  The most common reasons for admission among patients with PAN in this database were as follows; PAN itself (17.6%), sepsis (6.9%), acute kidney injury (4.9%), acute respiratory failure (2.1%) and pneumonia (2.0%). During hospitalization, a significantly higher morbidity among patients with PAN was observed as indicated by a significantly higher risk of shock (adjusted OR 1.75; 95% CI, 1.23 – 2.50), admission to ICU (adjusted OR 1.88; 95% CI, 1.44 – 2.45) and multi-organ failure (adjusted OR 3.12; 95% CI, 2.64 – 3.69) although the odds of mortality was not significantly elevated (adjusted OR 1.35; 95% CI, 0.91 – 2.00).  Patients with PAN also displayed significantly higher hospital costs (additional adjusted mean [aAM]: $9,693, p< 0.01), hospitalization charges (aAM: $34,273, p< 0.01) and LOS (aAM: 4.1 days, p< 0.01) compared to patients without PAN.  Analysis of comorbidities found a significant association between PAN and several comorbidities as shown in table 1.

Conclusion: The inpatient prevalence of PAN is higher than what would be expected from the overall general prevalence.  Hospitalizations of patients with PAN are associated with significantly higher rates of morbidity and expenditures.


Table 1

Table 1


Disclosure: P. Ungprasert, None; M. Koster, None; W. Cheungpasitporn, None; K. Wijarnpreecha, None; C. Thongprayoon, None; P. Kroner, None.

To cite this abstract in AMA style:

Ungprasert P, Koster M, Cheungpasitporn W, Wijarnpreecha K, Thongprayoon C, Kroner P. Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/inpatient-burden-expenditures-and-comorbidities-of-polyarteritis-nodosa-national-inpatient-sample-2014/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inpatient-burden-expenditures-and-comorbidities-of-polyarteritis-nodosa-national-inpatient-sample-2014/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology